Evaluating pregnancy risks in women with lung transplants
Immunologic Risk of Pregnancy in Women With Lung Transplant
This study is trying to understand the risks of pregnancy for women who have had lung transplants by looking at how their immune systems react to their babies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 1 Year and up |
| Sex | All |
| Sponsor | Nantes University Hospital Academic / other |
| Locations | 9 sites (Nantes, Loire Atlantique and 8 other locations) |
| Trial ID | NCT05689905 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the immunological risks associated with pregnancy in women who have undergone lung transplantation. It builds on previous research by examining the relationship between humoral rejection and the presence of common antigens between the child and the lung donor. The study will involve collecting HLA typing from children born to these women to identify potential immunological risks. The findings are expected to inform recommendations for managing pregnancies in lung transplant recipients.
Who should consider this trial
Good fit: Ideal candidates include children born to female lung transplant recipients in France between 2012 and 2021.
Not a fit: Patients who are not children of lung transplant recipients or those whose mothers did not consent to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide critical insights that help manage and reduce the immunological risks of pregnancy for women with lung transplants.
How similar studies have performed: While previous studies have explored related topics, this specific approach of evaluating humoral rejection risks in the context of pregnancy among lung transplant recipients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Children born between 01/01/2012 and 31/12/2021 of female patients over 18 years old with lung transplantation (mono, uni or cardio pulmonary) in France, * Alive at the time of our study. * Legal guardians' consent for oral swabbing of their child and HLA typing on this swab * Affiliated or beneficiaries of a social security system or similar Exclusion Criteria: - Refusal of consent by the patient and/or one of the two parents
Where this trial is running
Nantes, Loire Atlantique and 8 other locations
- Nantes University Hospital — Nantes, Loire Atlantique, France (Recruiting)
- Bordeaux University Hospital — Bordeaux, France (Recruiting)
- Grenoble University Hospital — Grenoble, France (Recruiting)
- Marie Lannelongue Hospital (GHSJ) — Le Plessis-Robinson, France (Recruiting)
- Civils Hospitals Lyon — Lyon, France (Recruiting)
- Ap-Hm — Marseille, France (Recruiting)
- Cochin Hospital (AP-HP) — Paris, France (Recruiting)
- Strasbourg University Hospital — Strasbourg, France (Recruiting)
- Foch Hospital — Suresnes, France (Recruiting)
Study contacts
- Study coordinator: Isabelle DANNER-BOUCHER
- Email: Isabelle.danner@chu-nantes.fr
- Phone: +33 2 40 16 52 67
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.